Amicus Therapeutics has kicked off the commercial launch of its rare disease therapy Galafold in the UK after it was endorsed for reimbursement within the NHS by the National Institute for Health and Care Excellence’s Highly Specialised Technologies Evaluation Committee.
Read More
Cost regulators for NHS therapies in England and Wales have now published final guidelines endorsing the use of Amicus Therapeutics’ Galafold for treating the rare genetic disorder Fabry disease.
Read More
Cost regulators for the NHS in England and Wales are backing use of a new therapy to treat the rare genetic disorder Fabry disease with a price tag of £210,000 per patient per year (excluding VAT and any discounts).
Read More
